Bakirtas, MDal, MSYigenoglu, TNGiden, AOSerin, IBasci, SKalpakci, YKorkmaz, SEkinci, OAlbayrak, MBasturk, AOzatli, DDogu, MHHacibekiroglu, TÇakar, MKUlas, TMiskioglu, MGulturk, EEser, BAltuntas, F2024-07-182024-07-181120-009X1973-9478http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10637A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least >= two lines of therapy. Patients' treatment responses, overall response rate, progression-free survival rate, and adverse events were recorded. Mean age of 54 patients was 66.5 +/- 9.1 years. There were 20 patients (37.0%) with progression. Median progression-free survival was 13 months in patients who received a median of three therapy lines in a 7.5-month follow-up period. Overall response rate was 38.5%. Of 54 patients, 19 (40.4%) had at least one adverse event, and nine (19.1%) had an adverse event of at least grade 3 or more. Of 72 adverse events observed in 47 patients, 68% were grade 1 or 2. Treatment was not stopped in any patient due to adverse events. IRd combination therapy was effective and safe in heavily treated RRMM patients.EnglishPROTEASOME INHIBITOR MLN9708ORAL IXAZOMIBANTITUMOR-ACTIVITYEFFICACYTRANSPLANTATIONCOMBINATIONMODELSCELLArticle